1. Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register;Scire;Ann Rheum Dis,2014
2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update;Smolen;Ann Rheum Dis,2014
3. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis;Finckh;Arthritis Rheum,2006
4. National Institute for Health and Care Excellence. TA375: adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. 2016. Available at: https://www.nice.org.uk/guidance/ta375. Accessed August 9, 2016.
5. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response;Gibbons;BioDrugs,2009